Trulieve posts Q3 2026 results and receives final DEA registrations after cannabis rescheduling
Trulieve Cannabis Corp. reported third‑quarter 2026 revenue of $230 million and a 64% gross margin. The company generated $74 million of operating cash flow, repaid a $65 million mortgage, and received final DEA registrations for its medical dispensaries following the federal rescheduling of marijuana to Schedule III. CEO Kim Rivers highlighted growth opportunities in Georgia and Texas and noted the removal of the 280E tax burden.
Why it matters
The earnings beat and strong cash generation improve Trulieve’s liquidity and profitability outlook, while the DEA registration and tax relief from rescheduling could enhance margins and attract institutional investors (the company says). The $65 million debt repayment reduces leverage and interest expense (the company reports).
Key facts
- 1Quarterly revenue was $230 million. prnewswire.com
- 2Gross margin for the quarter was 64%. prnewswire.com
- 3Net income attributable to common shareholders was $1 million. prnewswire.com
- 4Operating cash flow for the quarter was $74 million. sec.gov
- 5The company repaid $65 million of mortgage notes ahead of maturity. sec.gov
- 6Final DEA registrations were received for all state‑licensed medical dispensaries. sec.gov
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.